Detalhe da pesquisa
1.
Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
BJOG
; 2024 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38320967
2.
Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Int J Clin Pract
; 71(10)2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28906080
3.
Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Menopause
; 31(6): 512-521, 2024 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38626380
4.
Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey.
Menopause
; 30(12): 1179-1189, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37847872
5.
A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN).
Eur Urol Focus
; 2023 Oct 18.
Artigo
Inglês
| MEDLINE | ID: mdl-37863737